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ABSTRACT
Background: This study investigated the variations in the clinical efficacy and drug cost following the intro-
duction of the Asthma Prevention and Management Guidelines in Japan (JGL2003).
Methods: The medical charts of fifty outpatients treated continuously for asthma, aged 16-50 years, from Oc-
tober 2002 to October 2004 at Showa University Hospital were analyzed for physicians’ compliance with
asthma guidelines, symptom severity, episodes in various occasions, prescriptions and drug costs.
Results: Physicians’ compliance with the guidelines, which were defined as the number of patient visits
treated in conformity with the JGL over the total number of patient visits, was found to be high before (89.4%)
and after (90.3%) the introduction of JGL2003, without a statistical difference. On the other hand, the distribu-
tion of asthma symptom severity varied significantly (P < 0.0001). Fewer patients were recognized as having
more severe asthma symptoms after the introduction of JGL2003. Significantly more patients with severe
asthma symptoms were detected in the physicians’ noncompliant group than in the compliant group (P <
0.0001). The number of patients prescribed with oral corticosteroids, long-acting β2-agonists containing
patches, long-acting oral β2-agonists, short-acting inhaled β2-agonists, sustained-released theophylline and
leukotriene receptor antagonists decreased after the introduction of JGL2003. Furthermore, the total annual
drug cost per patient decreased significantly by an average of 16,259 yen (P = 0.006).
Conclusions: The JGL2003 was judged to have improved criteria, which thus resulted in the high compliance
of physicians with the guidelines, in the remission of asthma symptoms and in the reduction in the total annual
drug cost per patient.
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INTRODUCTION
Clinical guidelines are systematically developed state-
ments based on the scientific evidence of therapeutic
interventions. They help practitioners to diagnose or
to make decisions regarding the appropriate health
care under specific circumstances. The Japanese
guidelines for the management of asthma were pub-
lished for the first time in 1998 by a working group in
the Ministry of Health, Labour and Welfare, and enti-
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tled the Asthma Prevention and Management Guide-
lines in Japan (JGL1998). Subsequently, the guide-
lines were updated in 2000 and 2003 as JGL20001 and
JGL2003,2 respectively. The Global Initiative for
Asthma (GINA) was launched in 1995 as a collabora-
tive effort between the National Heart Lung and
Blood Institute (NHLBI) and the World Health Or-
ganization (WHO) and updated in 2002 (GINA2002).3
Both domestic and international guidelines recom-
mend the use of inhaled steroids in the treatment of
asthma. Inhaled corticosteroids (ICS) are found to be
effective in controlling the symptoms of asthma, thus
reducing asthma mortality rates.4 Many results sup-
port the benefit of inhaled steroids to control asth-
matic symptoms. One of the features in JGL2003 is
that the ICS is definitely recommended as the first-
line therapy in the treatment of mild-to-severe persis-
tent asthma in adults. Another feature in JGL2003 is
the introduction of new drugs, such as fluticasone
propionate, budesonide and long-acting inhaled β2-
agonists. In particular, the descriptions concerning
the recommended doses for various ICS depending
on the asthma symptom severity were added. The
use of long-acting inhaled β2-agonists was also added.
Furthermore, it also describes the peak expiratory
flow (%PEF) value and forced expiratory volume in
the 1st second (%FEV1) value as the definition of
asthma symptom severity in order to conform to the
GINA2002.5,6
de Marco R et al.7 reported a positive correlation
between good control of the disease and an adequate
dose of anti-inflammatory medication, which followed
the GINA recommendations. They also reported that
the patients treated without following the guidelines
experienced significantly more asthmatic attacks and,
thereby stressed the importance of compliance with
the guidelines. Pont et al.8 reported that patients
treated in accordance with the guidelines showed a
significantly higher overall health-related quality of
life than those treated without these guidelines.
Accordingly the effect of the guidelines was that
standard asthma treatment would become wide-
spread to many physicians. In consequence, asthma
control would be improved and asthma treatment
would reach a certain targeted level. The guidelines
are updated and revised continuously in order to in-
corporate any novel findings. Although some utility
evaluations of the asthma guidelines were investi-
gated, there have so far been no reports comparing
the actual conditions before and after the introduc-
tion of the asthma guidelines.
Therefore, this study investigated the variations in
the clinical efficacy and the drug costs following the
introduction of JGL2003, at a university hospital with
asthma specialists, where the effect of the guideline
revisions would be expected to promptly have an im-
pact.
METHODS
Various aspects of asthma treatment, such as physi-
cians’ compliance with asthma guidelines, symptom
severity, episodes in various occasions (i.e. hospital
admission, emergency department visit, unscheduled
emergency visit), prescription and drug costs were
compared between before and after the introduction
of JGL2003, which was updated on October 22, 2003.
All outpatients treated continuously for asthma
(aged 16-50 years) at Showa University Hospital were
selected and their medical charts were surveyed in
the present retrospectively study. The term of the
surveillance was 1 year before and after October 22,
2003, when JGL2003 was introduced. The outpatients
who regularly visited the hospital for more than 6
months before and after the introduction of JGL2003
were selected as the subjects of this study. The medi-
cal asthma treatments for adults are different from
those for children under the age of 16 and prescrip-
tions for patients aged 51 or over is often affected by
the other medicines other than those administered
for asthma. Therefore, the subjects were selected
within those age cut-offs.
This study employed the method of measuring
physicians’ compliance with the guidelines reported
by Pont et al.8 Physicians’ compliance with the guide-
lines, judged by the conformity to the JGL (Table 1,
2), was surveyed based on medical charts, prescrip-
tions, peak expiratory flows and symptoms for each
visit of the patients, and then were recorded as the
number of patient visits to be compliant or noncom-
pliant. Physicians’ compliance before and after the in-
troduction of the new guidelines (JGL2003) were as-
sessed based on whether they were compliant with
JGL2000 and JGL2003 or not, respectively. Physicians
were determined to be noncompliant when their
treatments included any violation of JGL. For exam-
ple, a physician who prescribed only ICS for a patient
with severe persistent asthma was judged to be non-
compliant, since other drugs should be administered
concomitantly with ICS.
The Cochran-Mantel-Haenszel chi square test,
stratified by individual patients, was employed to sta-
tistically evaluate the three sets of associations be-
tween the change in the guidelines and the physi-
cians’ compliance, between the asthma symptom se-
verity and the status of physicians’ compliance, and
between the guideline change and the asthma symp-
tom severity. The analyses of prescription or asthma
episodes were performed using McNemar’s test. The
drug cost and the number of concomitantly adminis-
tered drugs were analyzed using the Wilcoxon sign
rank test. The drug cost was calculated in one-year
unit as the annual drug cost per patient. All analyses
were performed using the JMP version 6 (SAS Insti-
tute, Cary, NC, USA) statistical software package.
With respect to ethical considerations, the protec-
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Table 1 Severity classification and treatment recommendations for JGL2000†
Severe persistent 
(Step 4)
Moderate persistent 
(Step 3)
Mild persistent
(Step 2)
Mild intermitent 
(Step 1)
Symptoms:
Frequent exacerba-
tions, Continual,
Limited daily activity
Night time symptoms:
Frequent
(Oral corticosteroids 
use continuously)
Lung function (PEF or 
FEV1):
<60% predicted/ per-
sonal best
Variability: >30%
Symptoms: 
Chronic, Almost daily 
use of inhaled SABA 
is necessary,
Disorder of daily ac-
tivity and sleep: 
≥once a week 
Night time symptoms: 
≥Once a week
Lung function ( PEF 
or FEV1):
60-70% predicted/ 
personal best
Variability: >30%
Symptoms:
≥Twice a week
Disorder of daily ac-
tivity and sleep:
≥Twice a month
Night time symptoms:
≥Twice a month
Lung function (PEF or 
FEV1):
70-80% predicted/ 
personal best
Variability: 20-30%
Symptoms:
Wheeze, Cough, or 
Dyspnea,
≤once or twice a 
week
Intermitent and brief
Night time symptoms:
≤Once or twice a 
month
Lung function (PEF or 
FEV1):
>80% predicted/ per-
sonal best
Variability <20%
Severity
classification‡
• High-dose ICS:
BDP 800-1600 μg/day
or FP 400-800 μg/day
• Oral corticosteroids:
Short term: Medium or 
high-dose, Maintenance 
dose: Minimum-
dose/day or alternate-
day
• Sustained-release the-
ophyline
• Patches/ Oral/Inhaled 
LABA
• Antialergic agents
1) LTRAs/TXA receptor 
antagonist/ TXA 
synthase inhibitor
• Inhaled SABA: used as 
needed
(≤third or 4th/day)
• Medium-dose ICS: 
BDP 400-800 μg/day 
or FP 200-400 μg/day
• Sustained-release 
theophyline
• Patches/Oral/Inhaled 
LABA
• Antialergic agents
1) LTRAs/TXA recep-
tor antagonist/ TXA 
synthase inhibitor
2) CMRI/H1 blocker/ 
Th2 cytokine inhibitor
• Inhaled anticholiner-
gic drugs
• Inhaled SABA: used 
as needed
(≤third or 4th/day)
• Low-dose ICS:
BDP 200-400 μg/day 
or FP 100-200 μg/day
• Sustained-release 
theophyline
• Antialergic agents
1) LTRAs/TXA recep-
tor antagonist/ TXA 
synthase inhibitor.
2) CMRI/H1 blocker/ 
Th2 cytokine inhibitor
• Patches/Oral/Inhaled 
LABA
• Inhaled SABA: used 
as needed
(≤third or 4th/day)
• Inhaled/oral SABA, or 
theophyline as needed
• Inhaled SABA or 
inhaled DSCG before 
exercise or exposure 
of alergen
• Antialergic agents
1) LTRAs/TXA recep-
tor antagonist/TXA 
synthase inhibitor
2) CMRI/H1 blocker/ 
Th2 cytokine inhibitor
• ICS: BDP 200 μg/ 
day or FP 100 μg/day
Medication
Recommend-
ations
†If asthma is not controled on the curent treatment regimen, then treatment should be stepped up until control is achieved. When 
control is maintained for at least three months, treatment can be stepped down.
‡The presence of one or more of the features of severity is suficient to place a patient in that category; an individual should be as-
signed to the most severe grade in which any feature occurs.
LTRAs, Leukotriene receptor antagonists; SABA, Short-acting β2-agonists; LABA, Long-acting β2-agonists; TXA, Thromboxane A2; 
DSCG, disodium cromoglycate; H1 blocker, Histamine H1-receptor blocker; CMRI, Chemical mediator release inhibitors.
tion of personal information was ensured by using the
anonymity with linking capability of the patients. The
institutional review boards at the Faculty of Pharma-
ceutical Sciences and at the University Hospital in
Showa University approved the study protocol.
RESULTS
Three hundred and sixty-six outpatients treated con-
tinuously for asthma from October 2002 to October
2004 at Showa University Hospital were screened.
Three hundred and ten of these patients were ex-
cluded because the patients had not been treated con-
tinuously before 2004. Six pregnant patients were
also excluded. As a result, 50 patients were recruited
for the study. The patient characteristics are shown
in Table 3. The terms of patient observation before
and after the introduction of JGL2003 ranged from 9
to 15 months (12 months on average) and from 6 to
15 months (11 months in average), respectively.
The physicians’ compliance accumulated for every
treatment day during the period with the adjustment
for patients was high before (448 total number of pa-
tient visits, 89.4%) and after (334 total number of pa-
tient visits, 90.3%) the introduction of JGL2003, re-
spectively. No remarkable difference was observed in
the physicians’ compliance before and after the intro-
duction of JGL2003. The physicians’ noncompliant re-
gimes are shown in Table 4.
On the other hand, the distribution of asthma
symptom severity, accumulated for every treatment
day during the period with the adjustment for pa-
tients, differed significantly (P < 0.0001) before and
after the introduction of JGL2003. Fewer patient visits
were recognized as having more severe asthma
Suzuki T et al.
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Table 2 Severity classification and treatment recommendations for JGL2003†
Severe persistent
(Step 4)
Moderate persistent 
(Step 3)
Mild persistent
(Step 2)
Mild intermitent
(Step 1)
Symptoms: 
Frequent exacerba-
tions, Daily, Limited 
daily activity
Night time symptoms: 
Frequent
Lung function (PEF or 
FEV1):
<60% predicted, 
Variability: ≥30%, or
PEF: <60% of per-
sonal best
Symptoms: 
Daily, Almost daily in-
haled SABA use 
Disorder of daily ac-
tivity and sleep: 
≥once a week 
Night time symptoms: 
≥Once a week
Lung function (PEF or 
FEV1):
60-80% predicted, 
Variability: ≥30%, or
PEF: 60-80% of per-
sonal best
Symptoms: 
More than once a 
week but less than 
once a day
Disorder of daily ac-
tivity and sleep:
≥once a month
Night time symptoms: 
≥ Twice a month
Lung function (PEF or 
FEV1):
≥80% predicted, 
Variability: 20-30%, or 
PEF ≥ 80% of per-
sonal best
Symptoms: 
<Once a week, mild, 
brief
Night time symptoms: 
Once or twice a 
month
Lung function (PEF or 
FEV1): 
≥80% predicted, 
Variability <20 %, or 
PEF ≥ 80 % of per-
sonal best
Severity 
classification‡
• High-dose ICS
Use of the more than 
one folowings with ICS
1) Sustained-release 
theophyline
2)Inhaled/Patches/Oral 
LABA
3) LTRAs
# Th2 cytokine inhibitor
• Uncontroled asthma 
with above mentioned 
medications
1) Concomitant use of 
oral corticosteroids
• Asthma atacks: In-
haled SABA, etc.
 
• Medium-dose ICS
Use of the one or more 
folowings with ICS
1) Sustained-release 
theophyline
2) Inhaled/Patches/
Oral LABA
3) LTRAs
#Th2 cytokine inhibitor
• Asthma atacks: 
Inhaled SABA, etc.
• Low-dose ICS
• Or use, or concomi-
tant use of the which-
ever folowing
1) Sustained-release 
theophyline, 
2) LTRAs, 3) DSCG
• Night time symptoms 
and persistent airway 
obstruction
1) Patches/Oral/
Inhaled LABA and 
ICS
• Atopic asthma: con-
comitant use of above 
mentioned medica-
tions
1) Antialergic agents
• Asthma atacks: 
Inhaled SABA, etc.
#Symptoms: once or 
twice a month, or blood 
or sputum eosinophilia
1) Lowest-dose ICS
2) Sustained-release 
theophyline
3) LTRAs, 
4) Antialergic agents
• Asthma atacks: 
Inhaled SABA, oral 
SABA, or short acting 
theophyline 
Medication 
recommenda-
tions
• : take continuously, #: alternative.
†If asthma is not controled on the curent treatment regimen, the treatment should be stepped up until control is achieved. When con-
trol is maintained for at least three months, treatment can be stepped down.
‡ The presence of one or more of the features of severity is suficient to place a patient in that category; an individual should be as-
signed to the most severe grade in which any feature occurs.
LTRAs, Leukotriene receptor antagonists; SABA, Short-acting β2-agonists; LABA, Long-acting β2-agonists; DSCG, disodium 
cromoglycate.
symptoms after the introduction of JGL2003 (Fig. 1).
The total number of patient visits in mild intermittent
and mild persistent asthma increased, while that in
moderate persistent asthma decreased, as accumu-
lated for every treatment day during the period.
The number of patient visits in each classification
of symptom severity, adjusted by the patients, was
found to be significantly different between the compli-
ant and noncompliant groups (P < 0.0001, Fig. 2).
More severe patients were found in the noncompliant
group than in the compliant group, especially for the
moderate and severe persistent asthma patients.
There was no significant difference in the inci-
dence of asthma episodes before and after the intro-
duction of JGL2003.
Differences were observed in the prescriptions be-
fore and after the introduction of JGL2003 (Fig. 3).
The number of patients that were prescribed with
oral corticosteroids, long-acting β2-agonist containing
patches, long-acting oral β2-agonists, short-acting in-
haled β2-agonists, sustained-released theophylline,
leukotriene receptor antagonists and APH-S signifi-
cantly decreased after the introduction of JGL2003,
according to McNemar’s test. In contrast, no signifi-
cant difference was observed in the number of pa-
tients receiving prescriptions for ICS, long-acting in-
haled β2-agonists and antiallergic agents, etc. The me-
dian number of concomitantly administered drugs
per patient decreased from 3.0 to 2.0 after the intro-
duction of JGL2003, with P = 0.0014.
Effects of JGL2003 on Asthma Therapy
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Table 3 Characteristics of the patients enroled in the present study
50No. of patients
(19-50）36.3 ± 7.9Age in years (range)
(54%/46%)27/23Gender ratio men/women (%)
(143-184)164.2 ± 9.2Body height (cm) (range)
(39.0-93.0)59.4 ± 11.3Body weight (kg) (range)
2 (4%)
(hyperlipidemia 1, faty liver 1, hypertension 1)No. of patients with concomitant disease (%)
(66%)33No. of patients with previous history (%)
(4%)2No. of patients with aspirin-induced asthma (%)
(18%)9No. of patients with atopic dermatitis (%)
(46%)23No. of patients with alergic rhinitis (%)
(28%)14No. of patients with asthma medical history in their family (%)
Smoking habits
31 : 8 : 10 (63% : 16% : 21%)
3 : 11 : 24 : 12
(6% : 22% : 48% : 24%)
 No. of patients (non-smokers : past smokers : curent smokers) (%)
No. of patients on the day of the initial visit with respect to asthma symptom 
severity (Mild intermitent : Mild persistent : Moderate persistent : Severe 
persistent) (%)
SD value is shown with the mean value when applied.
Table 4 Patients’ medication regimes
No. of patient visits (%)No. of patients (%)
782 (89.8)39 (78.0)Compliant regimes
 89 (10.2)11 (22.0)Noncompliant regimes
 13 (1.5)  1 (2.0) Not reduce the severity classification despite symptom improvement 
 36 (4.1)  5 (10.0)Only ICS, lacking other regimes, since other drugs should beadministered concomitantly with ICS 
 36 (4.1)  4 (8.0) Redundant use of long-acting β2-agonist as preventive medication
  3 (0.3)  2 (4.0) Other regimes lacking ICS, since ICS should be administered
  1 (0.1)  1 (2.0) Lower ICS’s doses than JGL’s recommendation
The total annual drug cost per patient significantly
decreased by 16,259 yen (Mean; P = 0.006) after the
introduction of JGL2003, as seen in Figure 4. Accord-
ing to the Wilcoxon test, each annual drug cost per
patient who received long-acting β2-agonist contain-
ing patches, long-acting oral β2-agonists, sustained-
released theophylline and APH-S was found to de-
crease by 5,297 yen (P = 0.03), 4,615 yen (P = 0.002),
2,087 yen (P = 0.002) and 631 yen (P = 0.03) after the
introduction of JGL2003, respectively.
DISCUSSION
Akiyama9 reported that from 30 to 40% of asthma phy-
sicians recognized JGL2003 and that over 90% of the
physicians knew of the revisions of JGL. Among
them, roughly 30% often used the JGL as a reference
and over 90% of the physicians partially used the JGL.
Lagerløv et al.10 found that most physicians agreed
with the guideline recommendations, however, the
proportion of asthma patients receiving inhaled ster-
oids remained around 44% (31-58%, depending on the
state). This may indicate that many physicians still do
not recognize the importance of the inflammatory
component of asthma. The use of ICS, recommended
as the first-line therapy in the treatment of mild-to-
severe persistent asthma in adults worldwide, is often
used as one of the indices of physicians’ compliance
with the guidelines. Only 23% of patients in Europe11
and 18% of patients in Japan12 are reportedly using
ICS. Rabe et al.13 reported that the use of anti-
inflammatory preventative medication, even in pa-
tients with severe persistent asthma, is low, ranging
from 26% in Western Europe to 9% in Japan. They
claim that such a proportion is lower than that over-
seas and that the use of the standard treatment rec-
ommended in the guidelines is not widespread. As
just described, the treatment in practice is rarely in
conformity with the guidelines for the management
of asthma. The method of selecting patients in the
previous surveys11-13 was by the random-digit tele-
phone sampling method. On the other hand, by the
method of questionnaires given to physicians, the
proportion of patients who use of ICS was reported to
be 77.4%.14 Makino et al.15 reported that JGL was rec-
ognized and utilized by most of the Japanese Society
of Allergology (JSA) members, but only half of non-
Suzuki T et al.
38 Allergology International Vol 59, No1, 2010 www.jsaweb.jp
Fig. 1 Comparison of the distribution of asthma symptom 
severity before and after the introduction of JGL2003. 
Asthma severity:  Mild intermitent  Mild persistent  
Moderate persistent  Severe persistent. The distribution 
of asthma symptom severity, accumulated for every treat-
ment day during the period was analyzed by the Cochran-
Mantel-Haenszel chi square test stratified by individual 
patients.
25
(6.8)
23
(4.6)
117
(31.9)
138
(27.5)
117
(31.9)
195
(38.8)
108
(29.4)
146
(29.1)
0% 20% 40% 60% 80% 100%
After
Before
Total Number of Patient Visits (%)
P < 0.0001
Fig. 2 Comparisons between the physician compliant 
group and noncompliant group. Asthma severity:  Mild in-
termitent  Mild persistent  Moderate persistent  Se-
vere persistent. The numbers of patient visits in each 
classification of symptom severity was analyzed by the 
Cochran-Mantel-Haenszel chi square test stratified by indi-
vidual patients. Physicians’ compliance before and after the 
introduction of the new guidelines (JGL2003) were as-
sessed based on whether they were compliant with 
JGL2000 and JGL2003 or not, respectively.
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255
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Inhaled anticholinergic drug
Inhibitor of chemical mediator release
APH-S†
Th2 cytokine inhibitor
Antiallergic agents
Leukotriene receptor antagonists
Sustained-released theophylline
Long-acting oral β2-agonists
Long-acting β2-agonist containing patches
Long-acting inhaled β2-agonists
Oral corticosteroids
Inhaled corticosteroids
No. of patients
Before
After
P = 0.0325
P = 0.0143
P = 0.0184
P = 0.0253
P = 0.0339
P = 0.0009
P = 0.0039
Fig. 3 Prescriptions before and after the introduction of JGL2003. The analyses of prescriptions were 
performed by McNemar’s test. 
† APH-S denotes the fulfiled prescription, including 3 mg clemastine, 0.6 g aminophyline, 3 mg tu-
lobuterol, 60 mg phenobarbital, 0.3 g magnesium oxide; 2 g Neo Umor®, and 1 g dried yeast.
member physicians were aware of JGL, although they
utilized JGL after they read it. However, conformity
with the guidelines in the hospital observed in the
current study was sufficiently high (the physicians’
compliance with guidelines was high with 89.4% even
before the introduction of JGL2003). Therefore, the
hospital surveyed in this study was thought to be ap-
propriate for investigating the effect of the revision of
JGL in asthma treatment. Treatment in this research
hospital was thought to have conformed to the JGL
because: 1) the physicians in the current study were
able to diagnose the patients’ asthma symptom sever-
ity and 2) the selected patients were regular outpa-
tients. No remarkable difference was observed in the
physicians’ compliance before and after the introduc-
tion of JGL2003, thus suggesting that no confusion
Effects of JGL2003 on Asthma Therapy
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Inhaled corticosteroids (48)
Oral corticosteroids (22)
Long-acting inhaled β2-agonists (11)
Long-acting β2-agonist containing patches (20) P = 0.03 
Long-acting oral β2-agonists (14) P = 0.002 
Short-acting inhaled β2-agonists (35)
Sustained-released theophylline (35) P = 0.002 
Leukotriene receptor antagonists (30)
Antiallergic agents (5)
Th2 cytokine inhibitor (2)
APH-S† (6) P = 0.03 
Inhibitor of chemical mediator release (2)
Inhaled anticholinergic drugs (1)
Total (50) P = 0.006 -16,249.1
-1,023.9
4,109.9
-630.5 
-9,941.0 
-21,755.9 
-11,160.4 
-2,087.2
-470.7 
-4,615.1 
-5,297.2
2,538.3
17.2
-2,512.8
Difference (After-Before) (yen)
-40,000 -30,000 -20,000 -10,000 0 10,000
Fig. 4 Comparison of annual drug cost per patient before and after the introduction of JGL2003. The 
analyses of each annual drug cost per patient before and after the introduction of JGL2003 were done 
using the Wilcoxon sign rank test (P). The diference represents the subtraction of each annual drug 
cost before from after the introduction of JGL2003. SE value is shown with the mean value. The num-
bers in parentheses denote those of samples. 
†  APH-S denotes the fulfiled prescription, including 3 mg clemastine, 0.6 g aminophyline, 3 mg tu-
lobuterol, 60 mg phenobarbital, 0.3 g magnesium oxide; 2 g Neo Umor®, and 1 g dried yeast.
had been caused by the revision of the JGL.
Significantly fewer patients were recognized to
have more severe asthma symptoms after the intro-
duction of JGL2003, thus indicating that the updated
guidelines were properly improved.
There were significantly more patients with more
severe asthma symptoms in the physicians’ noncom-
pliant group than in the compliant group (Fig. 2).
This result indicates two possibilities. One is that, the
more severe the asthma symptoms, the more compli-
cated the disease would be, therefore, it was more dif-
ficult to control asthma symptoms by following only
the asthma guidelines. Another is that treatment
without following the guidelines was unable to con-
trol the asthma symptoms.
Differences were observed in the use of prescrip-
tion medications (Fig. 3). The number of patients that
received oral corticosteroids, long-acting β2-agonist
containing patches, long-acting oral β2-agonists,
short-acting inhaled β2-agonists, sustained-released
theophylline and leukotriene receptor antagonists de-
creased after the introduction of JGL2003. The num-
ber of concomitantly administered drugs also de-
creased. In contrast, the number of patients pre-
scribed with other asthma medicines was not statisti-
cally significant.
One of the specific changes in the updated JGL
2003 is that the priority of using long-acting β2-
agonists, such as the inhalation, patch and oral medi-
cation, was established in this order. This may be the
reason why, the number of patients who received pre-
scriptions for long-acting β2-agonist containing
patches and long-acting oral β2-agonists was de-
creased. Meanwhile, the use of oral corticosteroids
was limited to the poorly controllable patients even if
all other kinds of asthma drugs were used among se-
vere persistent asthma patients. Therefore, it would
be natural that the number of patients who received
prescriptions for oral corticosteroids decreased.
ICS occupies a more important place in the guide-
lines after the introduction of JGL2003. However, the
number of patients prescribed with ICS was not sig-
nificantly different after the introduction of JGL2003.
This might be due to the effectiveness of ICS, which
had been extensively evaluated before the introduc-
tion of JGL2003.
After the introduction of JGL2003, ICS was defi-
nitely recommended as the best option for first-line
maintenance therapy for mild to severe persistent
asthma. As a result, the use of drugs other than ICS
was reasonably decreased and the number of con-
comitantly administered drugs also decreased. The
remission of asthma symptoms after the introduction
of JGL2003 is thought to also contribute to its de-
crease.
Another factor affecting the administration of pre-
scriptions by physicians would be the launch of new
drugs into the market. Generally, there are two such
Suzuki T et al.
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cases. The first case is that newly approved drugs, in
comparison with older ones, are more often pre-
scribed to patients due to the expectation of the new
effects. The second case is that newly approved drugs
are prescribed less since they are not yet common. In
the year before the introduction of JGL2003, Flutide
Diskus 100 and 200, Flutide Diskus 50, Flutide Air 50
and Serevent Rotadisk were launched January 2002,
February 2002, March 2003 and June 2002, respec-
tively. In the year after the introduction of JGL2003,
Flutide Air 100 and Serevent 50 Diskus were
launched in December 2003 and June 2004, respec-
tively. These drugs are classified as ICS or long-
acting inhaled β2-agonists. There were no differences
in the prescription of drugs after the introduction of
JGL2003. The drugs first launched in the year after
the introduction of JGL2003, Flutide Air 100 and Sere-
vent 50 Diskus were rarely prescribed in the first 3
and 2 patient visits, respectively. Consequently, the
launching of new drugs does not affect the prescrip-
tion rate.
The total annual drug cost per patient decreased
significantly by 16,259 yen (Mean) after the introduc-
tion of JGL2003. For this reason, the updated guide-
lines decreased the burden of patients’ medical costs
and contributed to the drug cost reduction. The effect
of decreased drug cost associated with generic drugs
was not included in this analysis, because there was
no prescription of generic drugs in the present study.
Antonicelli16 et al. reported that asthma severity, as
determined by the Global Initiative for Asthma classi-
fication, is significantly associated with the use of
asthma-related medical resources and the total medi-
cal expenses. Van Ganse17 et al. also reported that
medical costs increased significantly with decreasing
levels of control, independent of the symptom sever-
ity. The present study found that fewer patients were
recognized to have more severe asthma symptoms af-
ter the introduction of JGL2003, which may have
therefore contributed to the reduction of the medical
cost.
Although the asthma guidelines may not be per-
fect, they appear to be the best way to assist primary
care physicians and ensure that patients receive the
best possible care of their asthma. Despite the above-
mentioned advantages of asthma guidelines, patient
nonadherence with medication will lead to failure of
asthma control; therefore, patient education for
asthma is also an important factor in their manage-
ment.18 The asthma guidelines were updated in 2006
as JGL2006 in Japan19 and GINA2006 worldwide. The
primary revision in JGL2006 is that only ICS is defi-
nitely recommended as the first-line therapy in the
treatment of mild persistent asthma in adults. ICS is
thus considered to have played a more important role
in this sense.
In conclusion, JGL2003 was assessed to have im-
proved criteria, which resulted in the high compli-
ance of physicians with the guideline recommenda-
tions, in the remission of asthma symptoms and in
the reduction in the total annual drug cost per pa-
tient. However, there is a limitation of this study in
that the results were obtained at only one university
hospital; one must be careful in applying the same re-
sults to other university hospitals where physicians
need to be aware of JGL2003 to a similar extent.
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